<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158175">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02035293</url>
  </required_header>
  <id_info>
    <org_study_id>PEP</org_study_id>
    <secondary_id>RB 13-087  [CHRU Brest]</secondary_id>
    <nct_id>NCT02035293</nct_id>
  </id_info>
  <brief_title>Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>PEP</acronym>
  <official_title>Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A standardized diagnostic strategy of pulmonary embolism will be applied to eligible
      patients, incorporating a clinical probability score (revised Geneva score), plasma D-dimer
      assay and if necessary, a multidetector-row CT angiography thoracic and venous ultrasound of
      the lower limbs. All the patient with a pulmonary embolism diagnosed or not, will be
      followed for 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Frequency of pulmonary embolism in patients hospitalized for a clinical exacerbation of COPD.</measure>
    <time_frame>27 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of pulmonary embolism diagnosed during the 3 month follow-up in patients   whom pulmonary embolism was initially excluded when they've been included in the study</measure>
    <time_frame>27 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Patients Hospitalized for a COPD Exacerbation</condition>
  <arm_group>
    <arm_group_label>PEP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only following exams must be performed: a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a chest multidetector-row CT angiography and venous ultrasound of the lower limbs</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PEP</intervention_name>
    <arm_group_label>PEP</arm_group_label>
    <other_name>No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only exams must be performed;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients  hospitalized for a COPD exacerbation

          -  COPD previously diagnosed

        Exclusion Criteria:

          -  Allergy to iodinated contrast

          -  Creatinine clearance &lt; 30 mL / min

          -  Patient hospitalized for exacerbation of COPD for more than 48 hours

          -  Pneumothorax

          -  Exams impossible to be performed

          -  Pregnancy

          -  Life expectancy &lt; 3 months

          -  Patients already receiving anticoagulant therapy for another reason (mechanical
             valve, cardiac arrhythmia).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis COUTURAUD, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francis COUTURAUD, PU-PH</last_name>
    <email>francis.couturaud@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Marie ROY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis COUTURAUD, PU-PH</last_name>
      <email>francis.couturaud@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA</name>
      <address>
        <city>Brest</city>
        <zip>29240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NICOLAS PALEIRON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guy MEYER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>St-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick MISMETTI</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD Exacerbation</keyword>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Standardized and consensus diagnostic strategy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
